Important note: Information in this article was accurate in 2009. The state of the art may have changed since the publication date.
PRNewswire - October 13, 2009
Geneticist Jarrod Bailey, Ph.D., Science Director for Project R&R: Release and Restitution for Chimpanzees in U.S. Laboratories conducted a comprehensive analysis of the use of chimpanzees in cancer research over the past four decades as well as proposed future uses.
According to Bailey, "There are significant biological differences between humans and chimpanzees. Despite an overall - although superficial - genetic similarity to humans, and despite claims by the research industry, chimpanzees have proven to be a poor model for human cancer research."
The study found that chimpanzee tumors are extremely rare and biologically different from human cancers. Literature describing potential new cancer therapies tested in chimpanzees included significant caveats concerning species differences, and described interventions that had not been pursued in humans, presumably due to adverse reactions. Further, available evidence indicates that chimpanzees are not essential in the development of monoclonal antibody therapies for cancer treatment.
The U.S. is the only remaining large-scale user of chimpanzees in biomedical research in the world. Arguments regarding the inefficacy of chimpanzee use in biomedical research for humans have been mounting. H.R. 1326, the Great Ape Protection Act, was recently introduced to the House of Representatives. The bill seeks to end invasive biomedical research and testing on an estimated 1,000 chimpanzees remaining in U.S. laboratories.
The study concludes: "It would be unscientific to claim that chimpanzees are vital to cancer research and reasonable to conclude that cancer research would not suffer if the use of chimpanzees were prohibited in the U.S." The cancer paper follows other studies investigating chimpanzee use to study human health and disease, including HIV/AIDS vaccine development. That study found chimpanzee use has not benefited but rather has hindered our search for an effective human vaccine against HIV/AIDS.
Source: NEAVS/Project R&R
CONTACT: Karen Smith of NEAVS, +1-617-523-6020, Alternate: +1-917-701-7453, ksmith@neavs.org
Web Site: http://www.releasechimps.org/
091013
PR091007
Copyright © 2009 - PRNewswire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through PRNewswire, Permissions, 810 Seventh Ave., 32nd Floor, New York, NY 10019 http://www.prnewswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2009. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2009. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .